Pharma major Lupin Ltd on Wednesday said it has received approval from the U.S. health regulator to market its generic Varenicline tablets indicated for use as an aid to smoking cessation treatment.
The approval by the U.S. Food and Drug Administration is for the abbreviated new drug application for Varenicline tablets of strengths 0.5mg and 1mg, Lupin said in a regulatory filing.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
These are the generic equivalents of Chantix tablets, 0.5mg and 1mg, of PF Prism CV.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
"The product will be manufactured at Lupin's Pithampur facility in India," the company said.
Varenicline tablets, 0.5mg and 1mg, are indicated for use as an aid to smoking cessation treatment, it added.
Varenicline tablets had estimated annual sales of $430 million in the U.S., the company said, citing IQVIA MAT October 2023 data.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
